Canterbury DHB

Context

Chronic Myeloid Leukaemia

This is a complex area with the recent introduction of effective non-transplant treatments (e.g., Imatinib). See the CML section of the Red Book for a discussion of SCT Indications. For a further discussion of CML refractory to Imatinib, refer to Imatinib or Allograft? in the CML section.

References

About this Canterbury DHB document (8152):

Document Owner:

Andrew Butler (see Who's Who)

Issue Date:

December 2016

Next Review:

December 2018

Keywords:

Note: Only the electronic version is controlled. Once printed, this is no longer a controlled document. Disclaimer

Topic Code: 8152